{"filings":[{"id":778476,"accession_number":"0001628280-26-039518","cik":1434868,"company_name":"Esperion Therapeutics, Inc.","ticker":"ESPR","form_type":"8-K","filed_at":"2026-06-01T20:22:15+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Esperion shareholders approve 7M-share increase to 2022 equity incentive plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved Plan Amendment increasing 2022 Plan authorized shares by 7,000,000.","J. Martin Carroll and Sheldon L. Koenig elected as Class I directors for terms ending 2029.","Advisory vote on executive compensation approved with ~95.7M for, ~34.9M against.","Ratification of Ernst & Young as auditor for FY2026 passed with ~167.1M for.","All proposals passed at May 28, 2026 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":808336339.5527158,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92845,"accession_number":"0001104659-26-053482","cik":1434868,"company_name":"Esperion Therapeutics, Inc.","ticker":"ESPR","form_type":"8-K","filed_at":"2026-05-01T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Esperion acquired by ARCHIMED for $3.16/share plus up to $100M in milestone payments","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Cash $3.16/share + 1 CVR/share; aggregate milestone payments up to $100M based on net sales.","Milestone triggers: $40M if 2027 U.S. sales of bempedoic acid products >$350M; $60M if ENBUMYST sales >=$160M/year through 2030.","Close expected Q3 2026; conditions include stockholder approval, HSR clearance, and non-U.S. antitrust.","Board unanimously recommends; termination fees: $34.15M (Esperion), $68.3M (ARCHIMED).","Financing from ARCHIMED affiliates and third-party debt; no financing condition."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":1.0,"calibrated_materiality_score":1.0,"market_cap_usd":808336339.5527158,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92844,"accession_number":"0001628280-26-023196","cik":1434868,"company_name":"Esperion Therapeutics, Inc.","ticker":"ESPR","form_type":"8-K","filed_at":"2026-04-02T23:59:59+00:00","items":["1.01","2.01","2.03","7.01","9.01"],"status":"ready","headline":"Esperion closes $75M acquisition of Corstasis, adds Enbumyst nasal spray","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Closed acquisition of Corstasis Therapeutics for $75M cash upfront; up to $180M in milestones and royalties.","Acquired Enbumyst (bumetanide nasal spray), first FDA-approved nasal spray loop diuretic for edema.","Entered $25M term loan amendment and $50M royalty sale to Athyrium to partially finance the deal.","Enbumyst approved Sept 2025; Esperion plans commercial infrastructure to drive adoption.","Acquisition supports Vision 2040, diversifies cardiometabolic portfolio, expected revenue growth."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":808336339.5527158,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104017,"accession_number":"0001628280-26-016230","cik":1434868,"company_name":"Esperion Therapeutics, Inc.","ticker":"ESPR","form_type":"8-K","filed_at":"2026-03-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Esperion Q4 rev $168.4M (+144% Y/Y); FY25 rev $403.1M; Q4 net income $61.8M; acquires Corstasis","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["U.S. net product revenue Q4 $43.7M (+38% Y/Y); FY25 $159.6M (+38% Y/Y).","Collaboration revenue Q4 $124.7M (includes $90M Otsuka milestone); FY25 $243.6M (+12% Y/Y).","Q4 net income $61.8M ($0.26 basic EPS vs loss $0.11 in Q4 2024); FY25 net loss $22.7M narrowed from $51.7M.","Agreed to acquire Corstasis Therapeutics (Enbumyst nasal spray for CHF edema); targets $4B U.S. market.","Patent settlements restrict generic entry until April 2040; FY26 opex guidance $225-255M (incl ~$15M non-cash)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":808336339.5527158,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104016,"accession_number":"0001628280-26-013552","cik":1434868,"company_name":"Esperion Therapeutics, Inc.","ticker":"ESPR","form_type":"8-K","filed_at":"2026-03-03T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Esperion to acquire Corstasis for $75M upfront; adds Enbumyst nasal spray for heart failure edema","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Esperion acquires Corstasis for $75M cash upfront; up to $180M in milestones plus low double-digit royalties on Enbumyst sales.","Enbumyst (bumetanide nasal spray) is first FDA-approved nasal spray diuretic for edema in CHF, hepatic, renal disease (approved Sep 2025).","Esperion expects to leverage its cardiovascular commercial infrastructure to drive double-digit revenue growth; addresses $4B+ U.S. market.","Transaction financed via existing credit facilities and royalty monetization; expected close Q2 2026.","Corstasis also developing subcutaneous multidose pen injector; complements Esperion's pipeline in metabolic, hepatic, renal disease."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":808336339.5527158,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104015,"accession_number":"0001628280-26-001764","cik":1434868,"company_name":"Esperion Therapeutics, Inc.","ticker":"ESPR","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Esperion reports preliminary 2025 revenue up 20-23%, U.S. sales up 35-38%; provides 2026 OpEx guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary 2025 U.S. net product sales $156-160M, up 35-38% YoY; total revenue $400-408M, up 20-23%.","Cash and equivalents ~$168M at year-end 2025; completed $75M capital raise in 2025.","2026 operating expenses expected $210-245M, including $15M non-cash stock compensation.","Patent settlements with four ANDA filers restrict generic entry until April 2040; no remaining patent challenges.","R&D pipeline: nominated ESP-2001 (ACLY inhibitor) for primary sclerosing cholangitis; blockbuster potential >$1B."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":403135000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":808336339.5527158,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120298,"accession_number":"0001628280-25-049866","cik":1434868,"company_name":"Esperion Therapeutics, Inc.","ticker":"ESPR","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Esperion Q3 total revenue up 69% to $87.3M; net loss $0.16/share","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["U.S. net product revenue $40.7M (+31% YoY); total collaboration revenue $46.7M (+128% YoY).","Net loss $31.3M ($0.16 diluted EPS) vs $29.5M loss ($0.15) in Q3 2024.","Settled with Dr. Reddy's and three other ANDA filers; generic entry blocked until April 2040.","Partner Otsuka received Japan approval and preliminary pricing for NEXLETOL, triggering milestone payments.","Company reiterates 2025 opex guidance of $215-235M; expects sustainable profitability from Q1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.43,"consensus_revenue_estimate":null,"consensus_revenue_actual":234689000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":808336339.5527158,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120297,"accession_number":"0001628280-25-048557","cik":1434868,"company_name":"Esperion Therapeutics, Inc.","ticker":"ESPR","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Esperion appoints John Harlow as Chief Commercial Officer effective Nov 17, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["John Harlow appointed CCO; base salary $535,000, target bonus 45%, sign-on bonus $35,000.","Equity grants: option for 380,000 shares and 424,536 RSUs, vesting over four years.","Harlow previously CCO at Melinta Therapeutics, where revenue nearly doubled (~85% growth from 2020 to 2024).","He reports to CEO Sheldon Koenig and joins Esperion's Executive Leadership Team.","Harlow brings over 20 years of pharma commercial leadership from Melinta, Baudax Bio, Endo, Pfizer, and Novartis."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":808336339.5527158,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120296,"accession_number":"0001104659-25-097992","cik":1434868,"company_name":"Esperion Therapeutics, Inc.","ticker":"ESPR","form_type":"8-K","filed_at":"2025-10-08T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Esperion prices $75M public offering of 30M shares at $2.50 each","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 30,000,000 shares at $2.50/share; net proceeds ~$70.2M (or ~$80.7M if underwriters' option exercised).","Expected close October 9, 2025; use proceeds for NEXLETOL/NEXLIZET commercialization, R&D, working capital.","Piper Sandler & Cantor Fitzgerald are joint book-running managers; co-managers include Citizens JMP, H.C. Wainwright, Needham.","Shares sold under existing shelf registration statement (File No. 333-286631) effective April 29, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":808336339.5527158,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120295,"accession_number":"0001104659-25-097506","cik":1434868,"company_name":"Esperion Therapeutics, Inc.","ticker":"ESPR","form_type":"8-K","filed_at":"2025-10-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Esperion posts updated corporate presentation; no specific details provided","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company filed 8-K noting October 2025 corporate presentation posted to investor page.","Exhibit 99.1 is the corporate presentation, but its content was not disclosed in this filing.","No financial or strategic updates are available from the filing text or exhibit excerpt.","Investors should review the presentation at esperion.com/investors-media for material information."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":808336339.5527158,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136877,"accession_number":"0001628280-25-039392","cik":1434868,"company_name":"Esperion Therapeutics, Inc.","ticker":"ESPR","form_type":"8-K/A","filed_at":"2025-08-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Esperion amends Q2 earnings; reports $82.4M revenue, first operating income of $7.1M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss narrowed to $12.7M from $61.9M in Q2 2024; EPS loss $0.06 vs $0.33.","U.S. net product revenue rose 42% Y/Y to $40.3M; total revenue grew 12% to $82.4M.","Achieved $7.1M operating income, first quarter of positive operating income from ongoing ops.","Reached ANDA settlements blocking generic bempedoic acid until 2040.","Cash $86.1M at June 30; expects sustainable profitability starting Q1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":147380000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":808336339.5527158,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136879,"accession_number":"0001628280-25-037601","cik":1434868,"company_name":"Esperion Therapeutics, Inc.","ticker":"ESPR","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Esperion Q2 revenue $82.4M (+12% Y/Y); first operating income of $15M; expects sustainable profitability Q1 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["U.S. net product revenue $40.3M, +42% Y/Y; total prescriptions up 10% sequential.","Net loss per share $0.02 vs $0.33 loss a year ago; operating income from ongoing business $15M.","Reached settlements with three ANDA filers to block generic NEXLETOL until 2040.","Royalty revenue from European partner up 30% sequentially to $13.6M; Japan approval on track for H2 2025.","Reiterated FY2025 opex $215-235M; cash $86.1M; shares outstanding ~200.2M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":147380000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":808336339.5527158,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136878,"accession_number":"0001628280-25-033612","cik":1434868,"company_name":"Esperion Therapeutics, Inc.","ticker":"ESPR","form_type":"8-K","filed_at":"2025-07-01T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Esperion appoints Craig Thompson to Board of Directors; board now has eight members","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Craig Thompson appointed to Esperion Board as independent Class II director, effective July 1, 2025.","Board expands from seven to eight members; Thompson will serve on Compliance, Nominating/Gov., and Commercial Committees.","Thompson is CEO of Cerevance and has held leadership roles at Neurana, Anthera, Tetraphase, Trius, Pfizer, and Merck.","He led commercial development of torcetrapib/atorvastatin at Pfizer and was involved in Trius' $700M+ acquisition by Cubist.","Thompson holds a BComm from McMaster University and an MBA from the University of Notre Dame."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":808336339.5527158,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154109,"accession_number":"0001628280-25-028820","cik":1434868,"company_name":"Esperion Therapeutics, Inc.","ticker":"ESPR","form_type":"8-K","filed_at":"2025-06-02T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Esperion shareholders approve 6.25M share increase to 2022 stock plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved amendment to 2022 Stock Option and Incentive Plan, increasing authorized shares by 6,250,000.","Class III directors Jay P. Shepard (75.8M for) and Seth H.Z. Fischer (83.3M for) elected to board until 2028.","Advisory vote on executive compensation passed with 70.8M for, 26.7M against, 1.5M abstain.","Ratification of Ernst & Young as independent auditor for FY2025 approved: 118.2M for, 16.1M against.","Shares outstanding as of record date: 198,149,421; quorum of 136,468,661 shares present."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":808336339.5527158,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154108,"accession_number":"0001628280-25-022397","cik":1434868,"company_name":"Esperion Therapeutics, Inc.","ticker":"ESPR","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Esperion Q1 total revenue $65.0M (-53% Y/Y); US product revenue up 41% to $34.9M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $40.5M ($0.21 EPS loss) vs net income $61.0M ($0.36 EPS) in Q1 2024 due to prior-year milestone.","Collaboration revenue $30.1M (-73% Y/Y) on $100M milestone in Q1 2024; ex-milestone +97%.","Commercial: surpassed 1M US prescriptions; reimbursement team expanded from 5 to 15 specialists.","Pipeline: unveiled PSC candidate ESP-1336 (>$1B market); triple-combination products on track for 2027.","2025 op-ex guidance $215-235M (incl. ~$15M stock comp); cash $114.6M at quarter end."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":64995000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":808336339.5527158,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154107,"accession_number":"0001628280-25-016794","cik":1434868,"company_name":"Esperion Therapeutics, Inc.","ticker":"ESPR","form_type":"8-K","filed_at":"2025-04-04T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Esperion CCO Eric Warren to depart effective April 18, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Eric Warren stepping down as Chief Commercial Officer, effective April 18, 2025.","Departure not the result of any disagreement with the Company on operations, policies, or practices.","No successor or interim CCO announced in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":808336339.5527158,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154106,"accession_number":"0001628280-25-015901","cik":1434868,"company_name":"Esperion Therapeutics, Inc.","ticker":"ESPR","form_type":"8-K","filed_at":"2025-04-01T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Esperion appoints Robert E. Hoffman to board; two directors resign effective June 1","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Nicole Vitullo and Antonio M. Gotto, Jr., M.D., D.Phil. resign from board effective June 1, 2025; no disagreement cited.","Robert E. Hoffman elected independent director effective April 1, 2025; will chair Audit Committee from May 29, 2025.","Hoffman brings CFO and CEO experience from Heron, AnaptysBio, Arena, Kintara, and multiple biotech boards."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":808336339.5527158,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172720,"accession_number":"0001628280-25-009619","cik":1434868,"company_name":"Esperion Therapeutics, Inc.","ticker":"ESPR","form_type":"8-K","filed_at":"2025-03-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Esperion FY24 revenue $332.3M (+186% Y/Y); net loss narrows to $51.7M from $209.2M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY24 total revenue $332.3M (+186% Y/Y); Q4 revenue $69.1M (+114% Y/Y).","U.S. net product revenue FY24 $115.7M (+48% Y/Y); Q4 $31.6M (+52% Y/Y).","FY24 net loss $51.7M ($0.28/sh) vs $209.2M ($2.03/sh) in 2023; Q4 net loss $21.3M ($0.11/sh).","Announced development of two triple combination products with bempedoic acid.","Strengthened balance sheet: $304.7M from OMERS royalty deal; repaid $210M convertible debt; cash $144.8M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":808336339.5527158,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172719,"accession_number":"0001628280-25-001672","cik":1434868,"company_name":"Esperion Therapeutics, Inc.","ticker":"ESPR","form_type":"8-K","filed_at":"2025-01-16T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Esperion provides FY2025 expense guidance at J.P. Morgan Conference","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["R&D expenses expected $55M to $65M for FY2025.","SG&A expenses expected $160M to $170M for FY2025.","Total operating expenses expected $215M to $235M for FY2025.","Guidance announced at 43rd Annual J.P. Morgan Healthcare Conference on Jan 15, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":808336339.5527158,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189739,"accession_number":"0001104659-24-129592","cik":1434868,"company_name":"Esperion Therapeutics, Inc.","ticker":"ESPR","form_type":"8-K","filed_at":"2024-12-18T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Esperion completes $100M convertible note issuance and exchange of 2025 notes","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $100M aggregate principal of 5.75% Convertible Senior Subordinated Notes due June 15, 2030.","Exchanged ~$210.1M of existing 4.00% 2025 Notes for ~$57.5M new notes plus ~$153.4M cash.","Sold ~$42.5M of new notes for cash; net proceeds for general corporate purposes.","Initial conversion rate 326.7974 shares per $1,000 principal, conversion price ~$3.06 per share.","New notes are senior unsecured, redeemable after Dec 20, 2027 under certain conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":808336339.5527158,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189738,"accession_number":"0001104659-24-128212","cik":1434868,"company_name":"Esperion Therapeutics, Inc.","ticker":"ESPR","form_type":"8-K","filed_at":"2024-12-13T23:59:59+00:00","items":["1.01","2.03","3.02","8.01","9.01"],"status":"ready","headline":"Esperion closes $150M term loan and $210M convertible debt exchange to refinance 2025 notes","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Entered $150M senior secured term loan at 9.75% cash / 11.75% PIK, due Dec 2029, with minimum liquidity covenant of $50M.","Exchanged ~$210.1M of 4% 2025 notes for $57.5M in new 5.75% notes due 2030 and $153.4M cash; ~$42.5M raised via subscription for new notes.","New notes due 2030 have a conversion rate of 326.7974 shares/$1,000 (approx $3.06/share) and are redeemable from Dec 2027 at 130% threshold.","Proceeds from term loan and subscription will fund cash portion of exchange and general corporate purposes.","After closing, ~$54.9M of 2025 notes remain outstanding with unchanged terms."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":808336339.5527158,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189737,"accession_number":"0001628280-24-045984","cik":1434868,"company_name":"Esperion Therapeutics, Inc.","ticker":"ESPR","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Esperion Q3 revenue $51.6M (+52% YoY); net loss narrows to $29.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $51.6M (+52% YoY); U.S. net product revenue $31.1M (+53% YoY).","Net loss $29.5M (EPS -$0.15) vs. $41.3M loss (-$0.37) in Q3 2023.","Cash & equivalents $144.7M at Sep 30, up from $82.2M at Dec 31, 2023.","Retail prescription equivalents +12% QoQ; Oct 2024 TRx +17% vs. first 4 weeks of Q3.","European partner DSE royalty revenue $8.9M (+19% sequentially); Otsuka on track for Japan NDA filing by end 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.17,"consensus_revenue_estimate":null,"consensus_revenue_actual":263201000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":808336339.5527158,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206248,"accession_number":"0001628280-24-036597","cik":1434868,"company_name":"Esperion Therapeutics, Inc.","ticker":"ESPR","form_type":"8-K","filed_at":"2024-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Esperion Q2 revenue jumps 186% to $73.8M; monetizes European royalties for $304.7M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $73.8M (+186% YoY); U.S. product revenue $28.3M (+39% YoY).","Monetized European royalties to OMERS for $304.7M; used proceeds to pay off Oberland facility and remove liens.","Net loss $61.9M ($0.33 loss per share) vs $49.9M loss in Q2 2023; cash $189.3M.","Retail prescription equivalents increased 11% in final four weeks of Q2; >21,000 prescribers.","Reiterated FY2024 operating expense guidance $225M-$245M; patent extension for bempedoic acid to Dec 2030."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":211569000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":808336339.5527158,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206247,"accession_number":"0001628280-24-034766","cik":1434868,"company_name":"Esperion Therapeutics, Inc.","ticker":"ESPR","form_type":"8-K","filed_at":"2024-08-05T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Esperion CMO JoAnne Foody to depart by Sept 16; transition to Senior Advisor effective Aug 5","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["JoAnne Foody steps down as CMO effective Aug 5; remains as Senior Advisor until Sep 16.","Severance includes 12 months salary, health coverage, prorated FY2024 bonus, extended option exercise.","Transition Agreement signed Aug 3; Foody to cooperate as Senior Advisor on requested basis.","No successor named; search for new CMO presumably underway."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":808336339.5527158,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223321,"accession_number":"0001628280-24-030403","cik":1434868,"company_name":"Esperion Therapeutics, Inc.","ticker":"ESPR","form_type":"8-K","filed_at":"2024-06-28T23:59:59+00:00","items":["1.01","1.02","8.01","9.01"],"status":"ready","headline":"Esperion monetizes European bempedoic acid royalties for $304.7M, pays off Oberland facility","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Received $304.7M from OMERS in exchange for 100% of European bempedoic acid royalty until OMERS receives 1.7x investment (≈$518M), then royalties revert to Esperion.","Used proceeds to early payoff and termination of Oberland Capital revenue interest facility for $343.75M cash, removing senior secured liens.","Esperion retains potential future commercial milestones from DSE of up to $300M based on net sales thresholds.","Royalty to OMERS is tiered 15-25% of DSE net sales; Esperion regains full royalty stream after cap is reached.","CFO Ben Halladay cited enhanced balance sheet and increased operational flexibility to focus on U.S. commercialization."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":808336339.5527158,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223320,"accession_number":"0001628280-24-025418","cik":1434868,"company_name":"Esperion Therapeutics, Inc.","ticker":"ESPR","form_type":"8-K","filed_at":"2024-05-28T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Esperion shareholders approve 6.25M share increase to 2022 stock plan and 6.175M increase to ESPP","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Stockholders re-elected directors Antonio M. Gotto Jr. and Nicole Vitullo with 87.9M and 91.0M votes for, respectively.","Advisory say-on-pay proposal approved with 70.7M votes (74% of votes cast).","Ratification of Ernst & Young as auditor for FY2024 approved with 136.8M votes (98.3% of votes cast).","Amendment to 2022 Stock Option Plan increasing authorized shares by 6,250,000 approved with 88.1M votes.","Amendment to 2020 ESPP increasing reserved shares by 6,175,000 approved with 88.8M votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":808336339.5527158,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223319,"accession_number":"0001628280-24-021717","cik":1434868,"company_name":"Esperion Therapeutics, Inc.","ticker":"ESPR","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Esperion files Hatch-Waxman patent suit against Micro Labs over generic NEXLETOL","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Filed May 8, 2024 in District of New Jersey against Micro Labs USA Inc. for NEXLETOL generic ANDA.","Nine ANDA filers sent Paragraph IV certifications; lawsuit triggered 30-month FDA approval stay.","Esperion intends to file similar suits against remaining eight ANDA filers for NEXLETOL and NEXLIZET.","Complaint seeks injunction barring FDA approval and permanent injunction until patent expiration.","Litigation covers Orange-listed patents; company vows to vigorously defend IP."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":808336339.5527158,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223318,"accession_number":"0001628280-24-020841","cik":1434868,"company_name":"Esperion Therapeutics, Inc.","ticker":"ESPR","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Esperion Q1 revenue $137.7M (+467% YoY), net income of $61.0M; FDA label expansion expands market","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $137.7M vs $24.3M YoY; U.S. net product revenue $24.8M (+46% YoY).","Net income of $61.0M ($0.36 basic EPS) vs net loss of $61.7M in Q1 2023.","FDA approved label expansions for NEXLETOL/NEXLIZET to add CV risk reduction and use without statin.","Cash balance $226.6M at quarter end, up from $82.2M at Dec 31, 2023.","FY 2024 operating expense guidance maintained at $225M-$245M."],"consensus_eps_estimate":null,"consensus_eps_actual":0.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":137735000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":808336339.5527158,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}